Biochips Market Report 2026

Biochips Market Overview

• Biochips market size has reached to $14.61 billion in 2025 • Expected to grow to $29.03 billion in 2030 at a compound annual growth rate (CAGR) of 14.4% • Growth Driver: Impact of Personalized Medicine On Biochips Market • Market Trend: Advanced Technologies In Biochips Market Is Revolutionizing Drug Discovery With Organ-On-A-Chip Platforms • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Biochips Market?

Biochips are miniaturized devices containing an array of biological molecules, such as deoxyribonucleic acid (DNA), proteins, or cells, immobilized on a solid substrate. They combine biological elements with electronic systems to examine and handle biological data and are commonly used in medical diagnostics, genetic sequencing, and other biotechnological fields. The main types of biochips are deoxyribonucleic acid (DNA) chips, protein chips, lab-on-chip, tissue arrays, and cell arrays. DNA chips, also known as DNA microarrays, are tools used to analyze and monitor the expression of thousands of genes at once. Various technologies are included, such as microarrays and microfluidics. These have applications in drug discovery and development, agriculture, genomics, disease diagnostics, proteomics, and others and are used by a variety of end users, such as biotechnology and pharmaceutical companies, academic and research institutes, hospitals, diagnostic centers, and others.

What Is The Biochips Market Growth Forecast?

The biochips market size is expected to see rapid growth in the next few years. It will grow to $29.03 billion in 2030 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to rising demand for precision medicine and personalized therapies, growing utilization of lab-on-chip technologies in clinical testing, higher investment in biomarker discovery and translational research, expanding applications of biochips in agriculture and life sciences, increasing commercialization of advanced biochip-based diagnostic tools. Major trends in the forecast period include growing adoption of biochips in genetic sequencing and disease diagnostics, increasing use of protein and cell arrays for advanced biomolecular research, rising demand for lab-on-chip platforms in point-of-care testing, expansion of biochip applications in drug discovery and development, focus on miniaturization and high-throughput biological data analysis.

Global Biochips Market Segmentation

1) By Type: Deoxyribonucleic Acid (DNA) Chips, Protein Chips, Lab-On-Chip, Tissue Arrays, Cell Arrays 2) By Technology: Microarrays, Microfluidics 3) By Application: Drug Discovery And Development, Agriculture, Genomics, Disease Diagnostics, Proteomics, Other Applications 4) By End-User: Biotechnology And Pharmaceutical Companies, Academic And Research Institutes, Hospitals And Diagnostic Centers, Other End-Users Subsegments: 1) By Deoxyribonucleic Acid (Dna) Chips: Gene Expression Chips, Snp (Single Nucleotide Polymorphism) Chips, Dna Microarrays 2) By Protein Chips: Antibody Arrays, Protein Microarrays, Peptide Arrays 3) By Lab-On-Chip: Microfluidic Devices, Biosensors 4) By Tissue Arrays: Tumor Tissue Arrays, Normal Tissue Arrays 5) By Cell Arrays: Cell-Based Biochips, Cell Signaling Arrays

What Is The Driver Of The Biochips Market?

The increasing adoption of personalized medicines is expected to propel the growth of the biochips market going forward. Personalized medicine refers to tailoring medical treatment to individual characteristics, such as genetics or lifestyle, to optimize effectiveness and minimize adverse effects. The growing demand for personalized medicine is driven by its potential to provide more effective treatments, advancements in genomics, increasing disease complexity, and regulatory support. Biochips aid in personalized medicine by allowing for precise and individualized treatment plans tailored to a person's genetic profile. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to six in 2022. Therefore, the increasing adoption of personalized medicines is driving the growth of the biochips industry.

Key Players In The Global Biochips Market

Major companies operating in the biochips market are Thermo Fisher Scientific Inc., Roche Diagnostics International Ltd, Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Tecan Group Ltd., Cepheid Inc., Randox Laboratories Ltd., Takara Bio Inc., Luminex Corporation, Fluidigm Corporation, Micronit Microtechnologies B.V., Sphere Fluidics Limited, Sengenics, Arrayit Corporation, CustomArray Inc., NanoCellect Biomedical Inc., Dolomite Microfluidics, Biocartis NV

Global Biochips Market Trends and Insights

Major companies in the biochips market are concentrating their efforts on developing cutting-edge technologies like organ-on-a-chip platforms, aiming to revolutionize drug discovery and development processes. Organ-on-a-chip platforms are advanced microfluidic devices engineered to replicate the physiological characteristics and functions of human organs in a scaled-down format. For instance, in April 2024, Boston Micro Fabrication (BMF), a US-based nanotechnology research company, launched BMF Biotechnology Inc. BMF Biotechnology Inc. specializes in Biochips, also known as organ-on-a-chip platforms, designed to cultivate large-scale tissues in vitro. This innovation facilitates the accelerated development of new drugs and cosmetics by providing a platform for testing and research outside of the human body.

What Are Latest Mergers And Acquisitions In The Biochips Market?

In June 2023, Randox Laboratories, an Ireland-based health diagnostics company, acquired Cellix Limited for an undisclosed amount. Through this acquisition, Randox aims to enhance its technical expertise in benchtop flow cytometry, aligning with its dedication to personalized medicine and enhanced preventive healthcare. This move expands Randox's portfolio and the accessibility of flow cytometry technology to a broader range of scientists and clinicians. Cellix Limited is an Ireland-based company specializing in the creation of biochips for a wide range of applications across the life sciences.

Regional Outlook

North America was the largest region in the biochips market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Biochips Market?

The biochips market consists of sales of lab-on-a-chip (LOC) devices, cellular microarrays, and protein microarrays. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.